Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Quest Diagnostics Incorporated

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zevra Therapeutics (ZVRA), Roche Holding AG (RHHVF) and Quest Dia...

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Roche Holding AG (OtherRHHVF) and Quest Diagnostics (DGX)

Analysts fell to the sidelines weighing in on Harmony Biosciences Holdings (HRMY) and Quest Diagnostics (DGX) with neutral ratings, indicating that...

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Quest Diagnostics (DGX)

Truist Financial analyst David S Macdonald maintained a Hold rating on Quest Diagnostics today and set a price target of $250.00. S Macdonald cover...

Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX)

An announcement from Integrated Diagnostics Holdings ( ($GB:IDHC) ) is now available. A mandatory final cash offer at US$0.50 per share has been la...

IDH Board Rejects CEO-Led Mandatory Offer as Undervaluing Diagnostics Group

Stocks ended the week mixed as investors weighed a softer jobs report, lower Treasury yields, and renewed pressure on technology shares. The Dow Jo...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DGX	$227.86	-0.02%	1.54M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DGX	$227.86	-0.0%	1.54M
3
4
5
6

DGX

DGX

Get Quest Diagnostics Incorporated Data in Excel

Get Quest Diagnostics Incorporated Data in Excel